https://oncopeptides.com.haus.se/press-releases/ 2026-04-16T06:30:00+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides/ 2026-04-16T06:30:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides/ 2026-04-16T06:30:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/prekliniska-data-for-ny-nk-cellsengagerare-presenteras-vid-aacrs-arsmote-2026/ 2026-04-13T11:42:00+00:00 https://oncopeptides.com.haus.se/press-releases/preclinical-data-on-novel-nk-cell-engager-to-be-presented-at-the-aacr-annual-meeting-2026/ 2026-04-13T11:36:27+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-to-host-capital-markets-update-featuring-leading-global-experts-in-multiple-myeloma/ 2026-04-09T15:27:23+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-bjuder-in-till-capital-markets-update-med-ledande-globala-experter-inom-multipelt-myelom/ 2026-04-09T15:26:46+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-offentliggor-omsattning-for-fjarde-kvartalet-2025-och-uppdaterar-forvantningar-pa-kassaflodesmal/ 2026-04-09T15:21:59+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q3-report-2025/ 2026-04-09T15:18:37+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-tredje-kvartalet-2025/ 2026-04-09T15:17:59+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-announces-q4-2025-sales-and-updates-cash-flow-expectations/ 2026-04-09T14:58:19+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-year-end-report-2025/ 2026-04-09T11:49:56+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-initierar-studie-for-att-starka-real-world-evidens-for-pepaxti-i-tyskland/ 2026-04-09T11:45:18+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-14/ 2026-03-31T06:30:00+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-14/ 2026-03-31T06:30:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-initiates-marina-study-to-strengthen-real-world-evidence-for-pepaxti-in-germany/ 2026-03-26T13:24:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/utfall-i-oncopeptides-foretradesemission/ 2026-03-17T18:15:00+00:00 https://oncopeptides.com.haus.se/press-releases/outcome-in-oncopeptides-rights-issue/ 2026-03-17T18:15:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/european-journal-of-haematology-real-world-data-starker-pepaxtis-roll-i-behandlingssekvensen-vid-multipelt-myelom/ 2026-03-13T10:10:59+00:00 https://oncopeptides.com.haus.se/press-releases/european-journal-of-haematology-real-world-data-reinforces-pepaxtis-role-in-treatment-sequencing-for-multiple-myeloma/ 2026-03-13T10:09:30+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-erhaller-fast-track-status-for-window-of-opportunity-studie-i-glioblastom/ 2026-03-09T15:29:48+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-secures-fast-track-designation-for-window-of-opportunity-study-in-glioblastoma/ 2026-03-09T15:29:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q2-report-2025/ 2026-03-09T10:55:55+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-det-andra-kvartalet-2025/ 2026-03-09T10:55:41+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-disclosure-document-regarding-rights-issue-2/ 2026-03-09T10:19:53+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-year-end-report-2022/ 2026-03-02T10:16:12+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-bokslutskommuniken-for-2022/ 2026-03-02T10:16:12+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-receives-a-research-grant-from-swedens-innovation-agency-to-explore-the-pdc-platform-in-solid-tumors/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-far-forskningsanslag-fran-vinnova-for-att-utforska-pdc-plattformen-inom-solida-tumorer/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-presents-new-scientific-data-at-european-myeloma-network-meeting/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-presenterar-nya-vetenskapliga-data-vid-european-myeloma-network/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-year-end-report-2022/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-bokslutskommuniken-for-2022/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-cso-utredes-for-brott-mot-marknadsmissbrukslagen/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-cso-investigated-for-violation-of-the-market-abuse-act/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-cso-released-from-custody/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-cso-ej-langre-anhallen/ 2026-03-02T10:16:11+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides-ab-publ-8/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides-ab-publ-8/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-the-2022-annual-report/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-arsredovisningen-for-2022/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q1-report-2023/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-forsta-kvartalet-2023/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-issues-warrants-to-utilize-the-first-loan-tranche-from-eib/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-utfardar-teckningsoptioner-for-att-nyttja-forsta-lanetranchen-fran-eib/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q1-report-2023/ 2026-03-02T10:16:10+00:00 https://oncopeptides.com.haus.se/press-releases/correction-oncopeptides-presents-new-data-at-the-european-haematology-association-meeting/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/rattelse-oncopeptides-presenterar-nya-data-vid-european-haematology-associations-mote/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ-8/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-arsstamma-i-oncopeptides-ab-publ-8/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/press-releases/the-swedish-economic-crime-authority-terminates-the-investigation-of-oncopeptides-chief-scientific-officer-jakob-lindberg/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/ekobrottsmyndigheten-lagger-ned-utredningen-mot-oncopeptides-chief-scientific-officer-jakob-lindberg/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-forsta-kvartalet-2023/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-presents-new-data-at-the-european-haematology-association-meeting/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-presenterar-nya-data-vid-european-haematology-associations-mote/ 2026-03-02T10:16:09+00:00 https://oncopeptides.com.haus.se/press-releases/holger-lembrer-will-leave-his-role-as-chief-financial-officer-at-oncopeptides/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/holger-lembrer-lamnar-rollen-som-chief-financial-officer-pa-oncopeptides/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-complete-first-sales-of-pepaxti-in-greece/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-genomfor-forsta-forsaljningar-av-pepaxti-i-grekland/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/press-releases/issue-and-re-purchase-of-class-c-shares-for-shareholder-program-2/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/emission-och-aterkop-av-c-aktier-for-aktieagarprogram-2/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-13/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-13/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-andra-kvartalet-2023/ 2026-03-02T10:16:08+00:00 https://oncopeptides.com.haus.se/press-releases/sofia-heigis-appointed-ceo-of-oncopeptides-ab-publ/ 2026-03-02T10:16:07+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/sofia-heigis-utsedd-till-vd-for-oncopeptides-ab-publ/ 2026-03-02T10:16:07+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-appoints-henrik-bergentoft-as-chief-financial-officer/ 2026-03-02T10:16:07+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-utser-henrik-bergentoft-till-finanschef/ 2026-03-02T10:16:07+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-andra-kvartalet-2023/ 2026-03-02T10:16:07+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q2-report-2023/ 2026-03-02T10:16:07+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q2-report-2023/ 2026-03-02T10:16:07+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/information-gallande-oncopeptides-overklagande-i-usa-publicerad/ 2026-03-02T10:16:06+00:00 https://oncopeptides.com.haus.se/press-releases/information-regarding-oncopeptides-appeal-of-u-s-withdrawal-published/ 2026-03-02T10:16:06+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-two-articles-with-results-from-anchor-and-lighthouse-studies-in-haematologica/ 2026-03-02T10:16:06+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-tva-artiklar-med-resultat-fran-studierna-anchor-och-lighthouse-i-haematologica/ 2026-03-02T10:16:06+00:00 https://oncopeptides.com.haus.se/press-releases/chmp-issues-positive-opinion-on-type-ii-variation-to-extend-the-therapeutic-indication-of-pepaxti-based-on-ocean-trial-results/ 2026-03-02T10:16:06+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/chmp-ger-positivt-besked-om-typ-ii-variation-for-att-utvidga-den-terapeutiska-indikationen-av-pepaxti-baserat-pa-resultat-av-ocean-studie/ 2026-03-02T10:16:06+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-announces-successful-price-negotiations-for-pepaxti-in-germany/ 2026-03-02T10:16:06+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-tillkannager-framgangsrika-prisforhandlingar-for-pepaxti-i-tyskland/ 2026-03-02T10:16:06+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-12/ 2026-03-02T10:16:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-12/ 2026-03-02T10:16:05+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-announces-the-nomination-committee-3/ 2026-03-02T10:16:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-har-utsett-valberedningen-3/ 2026-03-02T10:16:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-tredje-kvartalet-2023/ 2026-03-02T10:16:05+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q3-report-2023/ 2026-03-02T10:16:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-valjer-att-avsluta-process-for-typ-ii-variation-for-pepaxti-i-syfte-att-optimera-patientnytta-och-aktieagarvarde/ 2026-03-02T10:16:05+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-opts-to-abandon-type-ii-variation-process-for-pepaxti-to-optimize-patient-and-shareholder-value/ 2026-03-02T10:16:05+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q3-report-2023/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-tredje-kvartalet-2023/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-chief-financial-officer-henrik-bergentoft-tilltrader-idag/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-chief-financial-officer-henrik-bergentoft-takes-office-today/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-selected-to-present-additional-data-from-ocean-study-at-the-american-society-of-hematology-meeting/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-utvalda-att-presentera-ytterligare-data-fran-ocean-studien-vid-american-society-of-hematology-kongress/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/press-releases/article-with-exploratory-alkylator-refractory-subgroup-analysis-from-oncopeptides-ocean-study-observing-longer-pfs-and-os-in-melflufen-vs-pomalidomide-published-in-european-journal-of-haemat/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/artikel-med-explorativ-alkylator-refraktar-subgruppsanalys-fran-oncopeptides-ocean-studie-som-observerar-langre-pfs-och-os-i-melflufen-jamfort-med-pomalidomid-publicerad-i-european-journal-of-hematolo/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/press-releases/update-on-the-type-ii-application-process/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/uppdatering-om-ansokningsprocessen-for-typ-ii/ 2026-03-02T10:16:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-sakerstaller-forlangd-marknadsexklusivitet-for-pepaxti-i-europa-med-fem-ar/ 2026-03-02T10:16:03+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ensures-five-years-extended-market-exclusivity-for-pepaxti-in-europe/ 2026-03-02T10:16:03+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-bokslutskommuniken-for-2023/ 2026-03-02T10:16:02+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-year-end-report-2023/ 2026-03-02T10:16:02+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-far-positiv-rekommendation-av-pepaxti-fran-den-spanska-prismyndigheten/ 2026-03-02T10:16:02+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-receives-positive-recommendation-for-pepaxti-by-spanish-pricing-authority/ 2026-03-02T10:16:02+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-receives-decision-from-the-u-s-food-and-drug-administration-confirming-withdrawal-of-pepaxto-from-the-u-s-market/ 2026-03-02T10:16:02+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-tar-emot-beslut-fran-u-s-food-and-drug-administration-som-bekraftar-tillbakadragande-av-pepaxto-fran-den-amerikanska-marknaden/ 2026-03-02T10:16:02+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-bokslutskommuniken-for-2023/ 2026-03-02T10:16:01+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-year-end-report-2023/ 2026-03-02T10:16:01+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/pepaxti-bibehaller-halsorelaterad-livskvalitet-visar-ocean-studien-artikel-publicerad-i-haematologica/ 2026-03-02T10:16:01+00:00 https://oncopeptides.com.haus.se/press-releases/pepaxti-provides-sustained-health-related-quality-of-life-ocean-study-shows-article-published-in-haematologica/ 2026-03-02T10:16:01+00:00 https://oncopeptides.com.haus.se/press-releases/extraordinary-general-meeting-in-oncopeptides-ab-publ-5/ 2026-03-02T10:16:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/extra-bolagsstamma-i-oncopeptides-ab-publ-5/ 2026-03-02T10:16:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-and-vector-pharma-fzco-announce-collaboration-to-provide-pepaxti-to-patients-in-the-middle-east-and-north-africa/ 2026-03-02T10:16:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-och-vector-pharma-fzco-tillkannager-samarbete-for-att-erbjuda-pepaxti-till-patienter-i-mellanostern-och-nordafrika/ 2026-03-02T10:16:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-port-studie-visar-att-perifer-venos-administrering-av-pepaxti-ar-lika-saker-som-central-venos-administrering/ 2026-03-02T10:16:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-port-study-shows-peripheral-administration-of-pepaxti-being-equally-safe-as-central-venous-administration/ 2026-03-02T10:16:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-carries-out-a-fully-guaranteed-rights-issue-of-approximately-sek-300-million-to-reach-profitability-during-2026/ 2026-03-02T10:16:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-genomfor-en-fullt-garanterad-foretradesemission-om-cirka-300-miljoner-kronor-for-att-na-lonsamhet-under-2026/ 2026-03-02T10:16:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-releases-first-quarter-2024-sales/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-offentliggor-forsaljning-for-forsta-kvartalet-2024/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-offentliggor-slutliga-villkor-for-den-fullt-garanterade-foretradesemissionen/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-announces-final-terms-for-the-fully-guaranteed-rights-issue/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-secures-national-reimbursement-for-pepaxti-in-spain/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-sakerstaller-nationell-subvention-for-pepaxti-i-spanien/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-an-extraordinary-general-meeting-in-oncopeptides-ab-publ/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-extra-bolagsstamma-i-oncopeptides-ab-publ-2/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-offentliggor-prospekt-avseende-foretradesemissionen/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-prospectus-relating-to-the-rights-issue/ 2026-03-02T10:15:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-arsredovisningen-for-2023/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides-ab-publ-7/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides-ab-publ-7/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-offentliggor-slutgiltigt-utfall-i-den-fullt-garanterade-foretradesemissionen/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-final-outcome-in-the-fully-guaranteed-rights-issue/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-presenterar-nya-data-som-belyser-behandlingsfordelarna-med-pepaxti-i-hogriskpatienter-med-multipelt-myelom-vid-comy-kongressen/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-presents-new-data-highlighting-treatment-benefits-of-pepaxti-in-high-risk-multiple-myeloma-patients-at-the-comy-congress/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q1-report-2024/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-forsta-kvartalet-2024/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-the-2023-annual-report/ 2026-03-02T10:15:58+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-11/ 2026-03-02T10:15:57+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/de-forsta-patienterna-i-spanien-behandlas-snart-med-pepaxti/ 2026-03-02T10:15:57+00:00 https://oncopeptides.com.haus.se/press-releases/first-patients-in-spain-to-be-treated-with-pepaxti/ 2026-03-02T10:15:57+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q1-report-2024/ 2026-03-02T10:15:57+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-det-forsta-kvartalet-2024/ 2026-03-02T10:15:57+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-issues-warrants-to-fulfil-its-obligations-under-loan-agreement-with-eib-2/ 2026-03-02T10:15:57+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-emitterar-teckningsoptioner-for-att-uppfylla-sina-skyldigheter-under-laneavtal-med-eib-2/ 2026-03-02T10:15:57+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-11/ 2026-03-02T10:15:57+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ-7/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-arsstamma-i-oncopeptides-ab-publ-7/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-utser-forsta-lakemedelskandidaten-fran-sin-spike-plattform/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-selects-first-candidate-drug-from-its-spike-platform/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-10/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-10/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/forsta-patienten-i-oncopeptides-studie-for-inhamtande-av-real-world-data-for-pepaxti-i-tyskland-rekryterad/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/press-releases/first-patient-enters-oncopeptides-study-aiming-to-gain-real-world-insights-from-pepaxti-in-germany/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q2-report-2024/ 2026-03-02T10:15:56+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-tredje-kvartalet-2024/ 2026-03-02T10:15:55+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-andra-kvartalet-2024/ 2026-03-02T10:15:55+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q2-report-2024/ 2026-03-02T10:15:55+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-det-andra-kvartalet-2024/ 2026-03-02T10:15:55+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-signs-license-agreement-with-scbio-for-pepaxti-in-south-korea/ 2026-03-02T10:15:55+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-tecknar-licensavtal-med-scbio-for-pepaxti-i-sydkorea/ 2026-03-02T10:15:55+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q3-report-2024/ 2026-03-02T10:15:55+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q3-report-2024/ 2026-03-02T10:15:54+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-det-tredje-kvartalet-2024/ 2026-03-02T10:15:54+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-inbjudna-att-presentera-data-om-effekten-av-pdc-plattformen-i-akut-myeloisk-leukemi-vid-american-society-of-hematology-kongress/ 2026-03-02T10:15:54+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-invited-to-present-data-on-pdc-platform-efficacy-in-acute-myeloid-leukemia-at-the-american-society-of-hematology-meeting/ 2026-03-02T10:15:54+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-har-utsett-valberedningen-2/ 2026-03-02T10:15:54+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-announces-the-nomination-committee-2/ 2026-03-02T10:15:54+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-bokslutskommuniken-for-2024/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/press-releases/strong-real-world-efficacy-and-safety-data-with-pepaxti-published-in-the-european-journal-of-haematology/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/starka-real-world-data-kring-effekt-och-sakerhet-for-pepaxti-publicerade-i-european-journal-of-haematology/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-erhaller-subvention-for-pepaxti-i-italien/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-obtains-reimbursement-for-pepaxti-in-italy/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-pepaxti-formellt-godkant-for-full-subvention-i-italien/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-pepaxti-formally-approved-for-full-reimbursement-in-italy/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/press-releases/jarl-ulf-jungnelius-resigns-from-oncopeptides-board-of-directors/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/jarl-ulf-jungnelius-lamnar-oncopeptides-styrelse/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-year-end-report-2024/ 2026-03-02T10:15:53+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-year-end-report-2024/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-bokslutskommuniken-for-2024/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/press-releases/issue-and-re-purchase-of-class-c-shares-for-shareholder-program/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/emission-och-aterkop-av-c-aktier-for-aktieagarprogram/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/press-releases/correction-issue-and-re-purchase-of-class-c-shares-for-shareholder-program/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/rattelse-emission-och-aterkop-av-c-aktier-for-aktieagarprogram/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-9/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-9/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-receives-first-order-of-pepaxti-in-italy/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-erhaller-sin-forsta-bestallning-av-pepaxti-i-italien/ 2026-03-02T10:15:52+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides-ab-publ-6/ 2026-03-02T10:15:51+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/nya-real-world-data-starker-evidensen-for-pepaxtis-effekt-och-tolerabilitet-hos-patienter-med-multipelt-myelom/ 2026-03-02T10:15:51+00:00 https://oncopeptides.com.haus.se/press-releases/new-real-world-data-support-effectiveness-and-tolerability-of-pepaxti-in-heavily-pretreated-multiple-myeloma-patients/ 2026-03-02T10:15:51+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-arsredovisningen-for-2024/ 2026-03-02T10:15:51+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/u-s-food-and-drug-administration-haver-kliniskt-stopp-for-oncopeptides-pipeline-lakemedel-opd5/ 2026-03-02T10:15:51+00:00 https://oncopeptides.com.haus.se/press-releases/u-s-food-and-drug-administration-removes-clinical-hold-of-oncopeptides-pipeline-drug-opd5/ 2026-03-02T10:15:51+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides-ab-publ-6/ 2026-03-02T10:15:51+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-the-2024-annual-report/ 2026-03-02T10:15:50+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-forsta-kvartalet-2025/ 2026-03-02T10:15:50+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q1-report-2025/ 2026-03-02T10:15:50+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q1-report-2025/ 2026-03-02T10:15:50+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-det-forsta-kvartalet-2025/ 2026-03-02T10:15:50+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-inleder-ny-real-world-studie-av-pepaxti-i-spanien-forsta-patienten-rekryterad/ 2026-03-02T10:15:50+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-launches-new-real-world-evidence-study-of-pepaxti-in-spain-first-patient-enrolled/ 2026-03-02T10:15:50+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-offentliggor-forsaljning-for-andra-kvartalet-2025/ 2026-03-02T10:15:49+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-meddelar-att-spansk-och-italiensk-real-world-data-accepterats-till-ims/ 2026-03-02T10:15:49+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-announces-acceptance-of-spanish-and-italian-real-world-data-at-ims-annual-meeting/ 2026-03-02T10:15:49+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-arsstamma-i-oncopeptides-ab-publ-6/ 2026-03-02T10:15:49+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ-6/ 2026-03-02T10:15:49+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-drug-pepaxti-included-in-european-guidelines-for-the-treatment-of-multiple-myeloma/ 2026-03-02T10:15:49+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-lakemedel-pepaxti-inkluderas-i-europeiska-riktlinjer-for-behandling-av-multipelt-myelom/ 2026-03-02T10:15:49+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-announces-net-sales-for-q2-2025/ 2026-03-02T10:15:49+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ingar-partnerskap-med-sd-pharma-for-att-ytterligare-starka-pepaxtis-rackvidd-i-spanien/ 2026-03-02T10:15:48+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-partners-with-sd-pharma-to-further-broaden-pepaxti-reach-in-spain/ 2026-03-02T10:15:48+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-rapporten-for-andra-kvartalet-2025/ 2026-03-02T10:15:48+00:00 https://oncopeptides.com.haus.se/press-releases/invitation-to-presentation-of-the-q2-report-2025/ 2026-03-02T10:15:48+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-genomfor-foretradesemission-om-cirka-150-msek-och-ger-en-uppdatering-om-det-potentiella-partnerskapet-i-japan/ 2026-03-02T10:15:48+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-carries-out-rights-issue-of-approximately-sek-150-million-and-provides-update-regarding-the-potential-partnership-in-japan/ 2026-03-02T10:15:48+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/ny-real-world-data-bekraftar-effektivitet-och-sakerhet-hos-pepaxti-presenteras-vid-ims-arliga-mote/ 2026-03-02T10:15:47+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-foretradesemission-overtecknad-till-cirka-157-procent/ 2026-03-02T10:15:47+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-rights-issue-oversubscribed-to-approximately-157-percent/ 2026-03-02T10:15:47+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ingar-ytterligare-garantiataganden-foretradesemissionen-fullt-garanterad/ 2026-03-02T10:15:47+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-enters-into-additional-guarantee-commitments-rights-issue-fully-guaranteed/ 2026-03-02T10:15:47+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-offentliggor-informationsdokument-avseende-foretradesemission/ 2026-03-02T10:15:47+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-disclosure-document-regarding-rights-issue/ 2026-03-02T10:15:47+00:00 https://oncopeptides.com.haus.se/press-releases/new-real-world-data-confirms-efficacy-and-safety-of-pepaxti-presented-at-ims-annual-meeting/ 2026-03-02T10:15:47+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-8/ 2026-03-02T10:15:46+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-8/ 2026-03-02T10:15:46+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-emitterar-teckningsoptioner-for-att-uppfylla-sina-skyldigheter-under-laneavtal-med-eib/ 2026-03-02T10:15:46+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-issues-warrants-to-fulfil-its-obligations-under-loan-agreement-with-eib/ 2026-03-02T10:15:46+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/journal-of-cancer-research-and-clinical-oncology-exceptionell-respons-pa-langtidsbehandling-med-pepaxti/ 2026-03-02T10:15:46+00:00 https://oncopeptides.com.haus.se/press-releases/journal-of-cancer-research-and-clinical-oncology-exceptional-long-term-responses-to-pepaxti/ 2026-03-02T10:15:46+00:00 https://oncopeptides.com.haus.se/press-releases/research-by-top-universities-together-with-oncopeptides-on-nk-cell-engagers-to-be-presented-at-ash/ 2026-03-02T10:15:45+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-q3-report-2025/ 2026-03-02T10:15:45+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-7/ 2026-03-02T10:15:45+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-7/ 2026-03-02T10:15:45+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/forskning-fran-ledande-universitet-tillsammans-med-oncopeptides-kring-nk-cellengagerare-presenteras-pa-ash/ 2026-03-02T10:15:45+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-rapporten-for-det-tredje-kvartalet-2025/ 2026-03-02T10:15:44+00:00 https://oncopeptides.com.haus.se/press-releases/annals-of-hematology-expert-consensus-supports-use-of-pepaxti-in-myeloma/ 2026-03-02T10:15:44+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/annals-of-hematology-experter-stodjer-anvandande-av-pepaxti-mot-myelom/ 2026-03-02T10:15:44+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-announces-the-nomination-committee/ 2026-03-02T10:15:44+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-har-utsett-valberedningen/ 2026-03-02T10:15:44+00:00 https://oncopeptides.com.haus.se/press-releases/research-shows-that-pepaxti-is-effective-in-high-risk-myeloma/ 2026-03-02T10:15:44+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/forskning-visar-att-pepaxti-ar-effektivt-vid-hogriskmyelom/ 2026-03-02T10:15:44+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-publishes-year-end-report-2025/ 2026-03-02T10:15:43+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-publicerar-bokslutskommuniken-for-2025/ 2026-03-02T10:15:43+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-offentliggor-informationsdokument-avseende-foretradesemission-2/ 2026-03-02T10:15:43+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/inbjudan-till-presentation-av-bokslutskommuniken-for-2025/ 2026-03-02T10:15:43+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-genomfor-en-foretradesemission-om-cirka-200-msek/ 2026-02-24T16:53:09+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-carries-out-a-rights-issue-of-approximately-sek-200-million/ 2026-02-24T16:51:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/fjarde-ledamoten-i-oncopeptides-valberedning-utsedd-infor-arsstamma-2017/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/abg-sundal-collier-ab-abgsc-has-notified-oncopeptides-ab-publ-that-stabilisation-measures-regarding-the-companys-shares-have-been-effected/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/press-releases/companys-ceo-acquires-shares-in-oncopeptides/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/bolagets-vd-forvarvar-aktier-i-oncopeptides/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-oncopeptides-ab-publ-2/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/press-releases/change-in-number-of-shares-and-votes-in-oncopeptides-ab-publ-2/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/abg-sundal-collier-ab-abgsc-has-notified-oncopeptides-ab-publ-that-stabilisation-measures-regarding-the-companys-shares-have-been-effected-2/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/abg-sundal-collier-ab-abgsc-har-meddelat-oncopeptides-ab-publ-att-stabiliseringsatgarder-avseende-bolagets-aktier-har-vidtagits/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/abg-sundal-collier-ab-abgsc-har-meddelat-oncopeptides-ab-publ-bolaget-att-stabiliseringsatgarder-avseende-bolagets-aktier-har-vidtagits-2/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/press-releases/abg-sundal-collier-ab-abgsc-has-notified-oncopeptides-ab-publ-that-stabilisation-measures-regarding-the-companys-shares-have-been-effected/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/press-releases/additional-patent-protection-for-ygalo-granted-in-europe-until-2032/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/ytterligare-patentskydd-for-ygalo-har-beviljas-i-europa-fram-till-2032/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/press-releases/fourth-member-of-oncopeptides-nomination-committee-appointed-for-the-2017-agm/ 2026-02-23T13:18:42+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/abg-sundal-collier-ab-abgsc-har-meddelat-oncopeptides-ab-publ-bolaget-att-stabiliseringsatgarder-avseende-bolagets-aktier-har-vidtagits/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/abg-sundal-collier-ab-utnyttjar-overtilldelningsoption-avseende-977-906-aktier-i-oncopeptides-ab-publ/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/abg-sundal-collier-ab-exercises-the-over-allotment-option-regarding-977906-shares-in-oncopeptides-ab-publ/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-emitterar-977-906-aktier-ytterligare-i-samband-med-erbjudande-om-forvarv-av-aktier-och-notering-pa-nasdaq-stockholm-erbjudandet/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-issues-977906-shares-additionally-in-connection-with-offer-to-acquire-shares-and-listing-on-nasdaq-stockholm-the-offering/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides-ab-publ-5/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides-ab-publ-5/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/press-releases/change-in-number-of-shares-and-votes-in-oncopeptides-ab-publ/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-oncopeptides-ab-publ/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-january-march-2017/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-kvartalsrapport-januari-mars-2017/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ-5/ 2026-02-23T13:18:41+00:00 https://oncopeptides.com.haus.se/press-releases/first-patient-dosed-in-the-pivotal-phase-iii-study-ocean-with-ygalo-melflufen/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-april-juni-2017/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-april-june-2017/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/valberedning-utsedd-infor-arsstamma-2018-i-oncopeptides/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/press-releases/nomination-committee-appointed-in-respect-of-agm-2018-in-oncopeptides/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-to-present-data-from-two-clinical-studies-of-ygalo-melflufen-at-american-society-of-hematology-ash-december-9-12/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-presenterar-data-fran-tva-kliniska-studier-med-ygalo-melflufen-pa-ash-american-society-of-hematology-den-9-12-december/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-kommer-att-delta-vid-jefferies-healthcare-conference-i-london-den-16-november/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-to-attend-the-jefferies-healthcare-conference-in-london-on-november-16th/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-juli-september-2017/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-arsstamma-i-oncopeptides-ab-publ-5/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/forsta-patienten-har-paborjat-behandling-i-den-pivotala-fas-iii-studien-ocean-med-ygalo-melflufen/ 2026-02-23T13:18:40+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-bokslutskommunike-2017/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/ytterligare-patentskydd-for-ygalo-har-beviljats-i-japan-fram-till-2033/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-avser-att-genomfora-en-riktad-nyemission-2/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-intends-to-make-a-directed-share-issue-2/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-july-september-2017/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-presenterade-idag-interimsdata-fran-den-pagaende-fas-ii-studien-horizon-med-ygalo-melflufen-pa-ashs-59e-arsmote/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-presented-interim-data-from-the-ongoing-phase-ii-study-horizon-with-ygalo-melflufen-at-the-59th-annual-meeting-of-ash-today/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-presenterade-idag-overlevnadsdata-fran-dess-fas-ii-studie-o-12-m1-med-ygalo-melflufen-pa-ashs-59e-arsmote/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-presented-survival-data-from-the-phase-ii-study-o-12-m1-of-ygalo-melflufen-at-the-59th-annual-meeting-of-ash-today/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-year-end-report-2017/ 2026-02-23T13:18:39+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-has-completed-a-directed-share-issue-of-approximately-sek-314-million/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-314-miljoner-kronor/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-forstarker-sin-ledningsgrupp-genom-utnamnande-av-dr-christian-jacques-som-evp-clinical-strategy-och-chief-scientific-officer/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-strengthens-its-management-team-with-dr-christian-jacques-as-evp-clinical-strategy-and-chief-scientific-officer/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-6/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-6/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/press-releases/first-patient-starts-treatment-in-oncopeptides-phase-i-ii-anchor-study-with-ygalo/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/forsta-patienten-har-paborjat-behandling-i-fas-i-ii-studien-anchor-med-ygalo/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides-ab-publ-4/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides-ab-publ-4/ 2026-02-23T13:18:38+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-annual-report-for-2017/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-arsredovisning-for-2017/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-har-tillsatt-en-clinical-advisory-board-bestaende-av-internationellt-erkanda-forskare-for-klinisk-utveckling-inom-hematologi/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-has-appointed-a-clinical-advisory-board-consisting-of-internationally-recognized-researchers-within-clinical-development-in-hematology/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-januari-mars-2018/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-january-march-2018/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ-4/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-arsstamma-i-oncopeptides-ab-publ-4/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/forberedelser-infor-en-framtida-kommersialisering-av-ygalo/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/press-releases/preparing-for-commercialisation-of-ygalo/ 2026-02-23T13:18:37+00:00 https://oncopeptides.com.haus.se/press-releases/anders-martin-lof-has-been-appointed-as-the-new-cfo-of-oncopeptides/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-utser-anders-martin-lof-som-ny-chief-financial-officer/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-to-present-at-the-jefferies-healthcare-conference-in-new-york-on-june-7th/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-kommer-att-presentera-vid-jefferies-healthcare-conference-i-new-york-den-7-juni/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-present-updated-interim-data-from-the-ongoing-horizon-trial-with-ygalo-at-the-23rd-congress-of-the-european-hematology-association-eha/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-presenterar-idag-uppdaterade-interimsdata-fran-den-pagaende-horizon-studien-med-ygalo-pa-det-europeiska-hematologimotet-eha/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/press-releases/interim-report-april-june-2018/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/delarsrapport-april-juni-2018/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-5/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-5/ 2026-02-23T13:18:36+00:00 https://oncopeptides.com.haus.se/press-releases/proposed-placing-in-oncopeptides-ab/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/press-releases/results-of-placing-in-oncopeptides-ab/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-4/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-4/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/press-releases/first-patient-starts-treatment-with-ygalo-in-oncopeptides-phase-ii-study-bridge-in-rrmm-patients-with-renal-impairment/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/forsta-patienten-har-paborjat-behandling-i-oncopeptides-fas-ii-studie-bridge-med-ygalo-i-rrmm-patienter-med-nedsatt-njurfunktion/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-kommer-att-presentera-vid-jefferies-london-healthcare-conference-den-14-november-2018/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-to-present-at-the-jefferies-london-healthcare-conference-on-november-14th/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/valberedning-utsedd-infor-arsstamma-2019-i-oncopeptides/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/press-releases/nomination-committee-appointed-in-respect-of-agm-2019-in-oncopeptides/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-to-host-a-capital-markets-day-in-new-york-on-december-14th/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-kommer-att-halla-en-kapitalmarknadsdag-i-new-york-den-14-december/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/press-releases/interim-report-july-september-2018/ 2026-02-23T13:18:35+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-3/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-3/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-to-present-updated-data-from-the-two-ongoing-trials-anchor-and-horizon-in-patients-with-rrmm-at-ash-in-december-2018/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-kommer-att-presentera-uppdaterade-data-fran-tva-pagaende-studier-anchor-och-horizon-i-rrmm-patienter-vid-ash-motet-i-december-2018/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/press-releases/extraordinary-general-meeting-in-oncopeptides-ab-publ-4/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/extra-bolagsstamma-i-oncopeptides-ab-publ-4/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/press-releases/additional-steps-towards-the-commercialization-of-ygalo/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/ytterligare-steg-i-arbetet-att-forbereda-infor-en-framtida-kommersialisering-av-ygalo/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides-2/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/delarsrapport-juli-september-2018/ 2026-02-23T13:18:34+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-extra-bolagstamma-i-oncopeptides-ab-publ-2/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-extraordinary-general-meeting-in-oncopeptides-ab-publ-3/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-capital-markets-day-december-14th-in-new-york/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-kapitalmarknadsdag-den-14-december-i-new-york/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-intends-to-make-a-directed-share-issue/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides-2/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-presenterar-de-forsta-interimsresultaten-fran-den-pagaende-kombinationsstudien-anchor-med-melflufen-vid-det-amerikanska-hematologimotet/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-presents-first-interim-data-from-the-ongoing-combination-trial-anchor-with-melflufen-at-the-60th-american-society-of-hematology-meeting/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/press-releases/interim-data-from-the-ongoing-horizon-trial-with-melflufen-presented-in-an-oral-presentation-at-the-60th-american-society-of-hematology-meeting/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/interimsdata-fran-den-pagaende-horizon-studien-med-melflufen-presenteras-i-en-muntlig-presentation-vid-det-60e-amerikanska-hematologimotet-ash/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/program-till-oncopeptides-kapitalmarknadsdag-den-14-december-2018/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/press-releases/program-for-oncopeptides-capital-markets-day-december-14th-2018/ 2026-02-23T13:18:33+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-data-fran-oncopeptides-kliniska-studier-horizon-och-anchor-dar-melflufen-utvarderas-i-rrmm-har-accepterats-for-presentation-vid-aacr-arsmote/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-avser-att-genomfora-en-riktad-nyemission/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-has-completed-a-directed-share-issue-of-approximately-sek-546-million/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-546-miljoner-kronor/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/antal-aktier-och-roster-i-oncopeptides/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/press-releases/number-of-shares-and-votes-in-oncopeptides/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-will-host-a-webcast-in-conjunction-with-its-year-end-report-2018-on-22-february-at-14-00-cet/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-kommer-att-halla-en-webbsandning-i-samband-med-bokslutskommuniken-for-2018-den-22-februari-klockan-14-00-cet/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-year-end-report-2018/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-bokslutskommunike-2018/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-kommer-att-presentera-vid-cowen-och-company-arliga-healthcare-konferens-mandagen-den-11-mars-kl-1610-est/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-to-present-at-the-cowen-and-company-annual-healthcare-conference-on-monday-11th-march-at-410-pm-eastern-standard-time/ 2026-02-23T13:18:32+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-data-from-oncopeptides-clinical-trials-horizon-and-anchor-evaluating-melflufen-in-rrmm-selected-for-presentation-at-the-aacr-annual-meeting/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-ytterligare-patentskydd-for-melflufen-har-beviljats-i-usa-fram-till-2033/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-additional-patent-protection-for-melflufen-granted-in-the-us-until-2033/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-updated-financial-calendar/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-uppdaterad-finansiell-kalender/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-arsstamma-i-oncopeptides-ab-publ/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-annual-general-meeting-in-oncopeptides-ab-publ/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-provides-new-guidance-on-the-patient-recruitment-in-the-ocean-study-and-a-clinical-program-update-in-a-webcast-at-1000-cet/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-kommer-att-ge-ny-vagledning-om-patientrekrytering-i-ocean-studien-och-en-klinisk-programuppdatering-i-en-webbsandning-klockan-1000-cet/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-annual-report-for-2018/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-arsredovisning-for-2018/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-melflufen-data-accepted-for-presentation-at-2019-asco-annual-meeting/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-meddelar-att-melflufen-data-har-accepterats-for-presentation-vid-ascos-arsmote-i-juni-2019/ 2026-02-23T13:18:31+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-to-apply-for-accelerated-approval-in-the-us/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-kommer-att-ansoka-om-villkorat-marknadsgodkannande-i-usa/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-q1-2019/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-q1-2019/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-kommunike-fran-arsstamma-i-oncopeptides-ab-publ/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-kommer-att-presentera-vid-jefferies-healthcare-conference-i-new-york-den-7-juni-klockan-11-30am-lokal-tid/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-to-present-at-the-jefferies-healthcare-conference-in-new-york-on-june-7th-at-11-30am-est/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-meddelar-att-fyra-abstrakt-gallande-melflufens-kliniska-program-godkants-for-presentation-vid-den-24e-eha-kongressen-i-juni-2019/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-acceptance-of-four-abstracts-highlighting-melflufen-clinical-programs-for-presentation-at-24th-eha-congress-in-june-2019/ 2026-02-23T13:18:30+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-avser-att-genomfora-en-riktad-nyemission-3/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-intends-to-make-a-directed-share-issue/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-new-data-from-oncopeptides-phase-1-2-o-12-m1-trial-evaluating-melflufen-in-rrmm-presented-at-2019-asco-annual-meeting/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-nya-data-fran-fas-1-2-studien-kallad-o-12-m1-med-melflufen-i-rrmm-patienter-vid-ascos-arsmote-2019/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-will-host-a-webcast-on-monday-17-june-at-0900-cet-to-review-and-update-presentations-from-european-hematology-eha-meeting/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-kommer-att-halla-en-webcast-mandagen-den-17-juni-klockan-0900-cet-for-genomgang-och-uppdatering-av-presentationer-fran-eha/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-nya-data-fran-fas-1-2-studien-anchor-med-melflufen-i-rrmm-patienter-vid-det-24e-europeiska-hematologimotet-eha/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-new-data-presented-at-24th-eha-congress-from-oncopeptides-phase-1-2-anchor-trial-evaluating-melflufen-in-relapsed-refractory-multiple-myeloma-rrmm/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-nya-data-presenterade-fran-oncopeptides-pivotala-fas-2-studie-horizon-med-melflufen-i-rrmm-patienter-vid-det-24e-europeiska-hematologimotet-eha/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-new-data-presented-from-oncopeptides-pivotal-phase-2-horizon-trial-evaluating-melflufen-in-relapsed-refractory-multiple-myeloma-at-24th-eha-congress/ 2026-02-23T13:18:29+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-727-miljoner-kronor/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-has-completed-a-directed-share-issue-of-approximately-sek-727-million/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-13/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-13/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-acceptance-of-data-for-presentation-at-international-myeloma-workshop-september-12-15/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-meddelar-att-data-accepterats-for-presentation-vid-international-myeloma-workshop-mellan-den-12-15-september/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-appoints-klaas-bakker-as-new-chief-medical-officer/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-utser-klaas-bakker-som-ny-chief-medical-officer/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-q2-2019/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-q2-2019/ 2026-02-23T13:18:28+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-meddelar-att-tva-postrar-presenterats-vid-international-myeloma-workshop/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-two-poster-presentations-at-the-international-myeloma-workshop/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-new-interim-data-in-rrmm-patients-with-extramedullary-disease-from-the-pivotal-phase-2-horizon-study-presented-at-international-myeloma-workshop/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-nya-interimsdata-i-rrmm-patienter-med-metastaserad-cancer-emd-fran-den-pivotala-fas-2-studien-horizon-presenteras-pa-international-myeloma-workshop/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-exercise-of-options-and-sale-of-shares-under-the-employee-stock-option-program-2012-2019/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-utnyttjande-av-optioner-och-forsaljning-av-aktier-under-personaloptionsprogram-2012-2019/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-den-pivotala-fas-2-studien-horizon-fardigrekryterad/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-nya-data-fran-oncopeptides-pivotala-fas-2-studie-horizon-i-patienter-med-metastaserad-cancer-extramedullar-sjukdom-emd-presenteras-den-15-september/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-new-updated-data-will-be-presented-from-oncopeptides-pivotal-phase-2-horizon-study-in-patients-with-extra-medullary-disease-emd-on-september-15th/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-data-fran-oncopeptides-kliniska-program-med-melflufen-presenterat-vid-society-of-hematologic-oncology-soho-arsmote/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-data-from-oncopeptides-melflufen-clinical-development-program-presented-at-soho-2019-annual-meeting/ 2026-02-23T13:18:27+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-kommer-att-publicera-data-fran-det-kliniska-programmet-for-melflufen-i-multipelt-myelom-och-al-amyloidos-i-sex-presentationer-pa-ash/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/press-releases/extraordinary-general-meeting-in-oncopeptides-ab-publ-3/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/extra-bolagsstamma-i-oncopeptides-ab-publ-3/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-q3-2019/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-patient-recruitment-in-the-pivotal-phase-2-study-horizon-completed/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-12/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-12/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/press-releases/sale-of-existing-shares-in-oncopeptides-ab/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-nomination-committee-appointed-in-respect-of-agm-2020-in-oncopeptides/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-valberedning-utsedd-infor-arsstamma-2020-i-oncopeptides/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-11/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-11/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-to-highlight-data-from-melflufen-clinical-program-in-multiple-myeloma-and-al-amyloidosis-in-six-presentations-at-ash-annual-meeting-2019/ 2026-02-23T13:18:26+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-starker-sin-regulatoriska-enhet-och-utser-karin-eklund-vanderpol-till-head-of-regulatory-affairs/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-q3-2019/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-appoints-joseph-horvat-as-president-north-america/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-utser-joseph-horvat-till-president-north-america/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-haller-en-webcast-tisdagen-den-10-december-klockan-1300-cet-avseende-data-som-presenteras-vid-ashs-arsmote/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-will-host-a-webcast-on-tuesday-december-10th-at-1300-cet-to-provide-an-update-regarding-data-presented-at-the-ash-annual-meeting/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-uppdaterade-effekt-och-sakerhetsdata-fran-den-pivotala-fas-2-studien-horizon-i-rrmm-patienter-vid-ashs-arsmote-2019/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-updated-efficacy-and-safety-data-from-pivotal-phase-2-horizon-study-in-patients-with-rrmm-at-ash-annual-meeting-2019/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-promising-data-from-the-phase-2-anchor-combination-study-in-patients-with-rrmm-at-ash-annual-meeting-2019/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-lovande-data-fran-fas-2-kombinationsstudien-anchor-i-patienter-med-rrmm-vid-ashs-arsmote-2019/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-extra-bolagsstamma-i-oncopeptides-ab-publ/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-extraordinary-general-meeting-in-oncopeptides-ab-publ-2/ 2026-02-23T13:18:25+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-kommer-att-halla-en-webcast-mandagen-den-27-januari-klockan-11-00-cet/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-will-host-a-webcast-on-monday-january-27th-at-11-00-cet/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-q4-2019/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-q4-2019/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-strengthens-its-organization-by-appointing-karolina-vilval-as-general-counsel/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-starker-sin-organisation-och-utser-karolina-vilval-till-chefjurist/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-informerar-om-hur-covid-19-paverkar-det-kliniska-utvecklingsprogrammet-for-melflufen/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-provides-update-regarding-covid-19-impact-on-the-melflufen-clinical-program/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-the-lancet-haematology-publishes-results-from-oncopeptides-multicenter-international-phase-1-2-study-o-12-m1/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-the-lancet-haematology-publicerar-resultat-fran-oncopeptides-internationella-multicenterstudie-o-12-m1/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-tillkannager-att-den-finala-tumorsvarsfrekvensen-i-den-pivotala-melflufenstudien-horizon-var-26-for-trippelklassrefraktara-rrmm-patienter/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-26-overall-response-rate-of-melflufen-in-triple-class-refractory-multiple-myeloma-patients-from-the-pivotal-horizon-study/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-strengthens-its-regulatory-function-by-appointing-karin-eklund-vanderpol-as-head-of-regulatory-affairs/ 2026-02-23T13:18:24+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides-ab-publ-3/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-arsredovisning-for-2019/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-annual-report-2019/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-avser-att-genomfora-en-riktad-nyemission-2/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-intends-to-carry-out-a-directed-share-issue-2/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-1-414-miljoner-kronor-144-musd/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-has-completed-a-directed-share-issue-raising-approximately-sek-1414-million-usd-144-m/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-strengthens-its-corporate-communications-function-by-appointing-rolf-gulliksen-as-global-head-of-corporate-communications/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-starker-sin-kommunikationsfunktion-genom-att-utse-rolf-gulliksen-till-global-kommunikationschef/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides-ab-publ-3/ 2026-02-23T13:18:23+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-q1-2020/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-arsstamma-i-oncopeptides-ab-publ-3/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-that-two-abstracts-on-multiple-myeloma-have-been-accepted-by-the-2020-asco-annual-meeting/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-tillkannager-att-tva-abstrakt-inom-multipelt-myelom-har-accepterats-av-american-society-of-clinical-oncologys-arsmote-2020/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-new-clinical-and-preclinical-melflufen-data-at-the-upcoming-european-hematology-association-meeting/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-offentliggor-nya-kliniska-och-prekliniska-data-for-melflufen-pa-det-kommande-arliga-hematologimotet-european-hematology-association/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-pre-clinical-melflufen-data-at-the-aacr-annual-meeting-2020-that-further-validates-the-technical-platform-pdc/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-prekliniska-data-for-melflufen-pa-den-amerikanska-cancerkongressen-aacr-2020-vilket-validerar-var-teknikplattform-pdc/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-slutfor-rekryteringen-till-den-pivotala-fas-3-studien-ocean-i-relapserande-refraktart-multipelt-myelom-450-patienter-har-inkluderats/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-completes-enrollment-to-the-pivotal-phase-3-study-ocean-for-relapsed-refractory-multiple-myeloma-450-patients-included/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-q1-2020/ 2026-02-23T13:18:22+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ-3/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-aterupptar-patientrekryteringen-till-kliniska-utvecklingsprogrammet-for-melflufen-efter-att-den-tillfalligt-pausats-pa-grund-av-covid-19-pandemin/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-reinitiates-patient-enrollment-to-the-melflufen-clinical-program-following-a-temporary-pause-due-to-the-covid-19-pandemic/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-10/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-10/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-ny-analys-bekraftar-att-patienter-med-multipelt-myelom-i-ocean-studien-star-kvar-pa-behandling-langre-an-vantat-resultat-forvantas-h1-2021/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-new-analysis-confirms-that-multiple-myeloma-patients-in-the-ocean-study-stay-on-treatment-longer-than-previously-estimated-results-expected-h1-2021/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-anordnar-ett-virtuellt-symposium-pa-europeiska-hematologimotet-european-hematology-association-om-utmaningar-vid-behandling-av-myelom/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-hosts-a-virtual-symposium-at-the-25th-european-hematology-association-congress-on-challenges-in-managing-patients-with-myeloma/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-redovisar-fullstandiga-data-fran-fas-2-studien-horizon-i-trippelklassrefraktara-patiente-r-med-multipelt-myelom/ 2026-02-23T13:18:21+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-lamnar-in-en-ansokan-om-villkorat-marknadsgodkannande-till-fda-for-patienter-med-trippelklassrefraktart-multipelt-myelom/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-9/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-9/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-leadership-changes-jakob-lindberg-assumes-a-new-role-as-cso-and-marty-j-duvall-is-appointed-ceo/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-offentliggor-ledarforandringar-jakob-lindberg-tar-over-rollen-som-forskningschef-och-marty-j-duvall-utses-till-vd/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-uppdaterad-version-oncopeptides-offentliggor-ledarforandringar-jakob-lindberg-tar-over-rollen-som-forskningschef-och-marty-j-duvall-utses-till-vd/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-reports-positive-results-from-full-data-set-of-phase-2-horizon-trial-in-triple-class-refractory-multiple-myeloma-patients/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-forstarker-den-prekliniska-forskningen-och-tar-over-kanceras-laboratorium-i-solna-for-lakemedelsutveckling-fran-den-1-juli/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-strengthens-the-pre-clinical-development-and-takes-over-kanceras-solna-based-laboratory-for-drug-development-as-of-july-1/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-submits-a-new-drug-application-to-the-fda-for-accelerated-approval-of-melflufen-in-triple-class-refractory-multiple-myeloma-patients/ 2026-02-23T13:18:20+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-8/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-8/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-starts-the-phase-2-port-study-comparing-peripheral-versus-central-administration-of-melflufen-and-dexamethasone-in-multiple-myeloma/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-startar-fas-2-studien-port-som-jamfor-perifer-administrering-med-central-administrering-av-melflufen-och-dexametason-vid-multipelt-myelom/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-initiates-the-first-study-with-melflufen-outside-multiple-myeloma-and-enrolls-the-first-patient-in-the-phase-1-2-al-amyloidosis-study/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-startar-den-forsta-studien-med-melflufen-utanfor-multipelt-myelom-och-rekryterar-den-forsta-patienten-till-fas-1-2-studien-i-al-amyloidos/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-q2-2020/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-q2-2020/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-fda-grants-priority-review-of-melflufen-for-patients-with-triple-class-refractory-multiple-myeloma/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-fda-beviljar-en-prioriterad-granskning-av-melflufen-for-patienter-med-trippelklassrefraktart-multipelt-myelom/ 2026-02-23T13:18:19+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-avslutar-den-utokade-rekryteringen-till-pivotala-fas-3-studien-ocean-pa-495-patienter-med-relapserande-refraktart-multipelt-myelom/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-completes-the-extended-enrollment-for-the-pivotal-phase-3-ocean-study-in-relapsed-refractory-multiple-myeloma-495-patients-included/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-samordnar-den-globala-och-amerikanska-organisationsstrukturen-och-utser-mohamed-ladha-till-general-manager-for-den-amerikanska-affarsenheten/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-further-aligns-the-us-and-global-organizational-structure-and-appoints-mohamed-ladha-as-general-manager-of-the-us-business-unit/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-initiates-u-s-expanded-access-program-with-melflufen-in-triple-class-refractory-multiple-myeloma/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-startar-ett-expanded-access-program-i-usa-med-melflufen-i-trippelklassrefraktart-multipelt-myelom/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-med-den-prioriterade-granskningen-pa-gang-inom-fda-gar-oncopeptides-vidare-for-att-ansoka-om-villkorat-godkannande-av-melflufen-hos-ema/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-with-the-priority-review-underway-at-fda-oncopeptides-moves-forward-with-intent-to-file-for-conditional-approval-of-melflufen-with-ema/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-signs-e-40-million-loan-agreement-with-the-eib/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-ingar-laneavtal-om-40-miljoner-euro-med-eib/ 2026-02-23T13:18:18+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-meddelar-att-nya-data-for-melflufen-accepterats-for-presentation-vid-arliga-amerikanska-hematologmotet-ash/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-that-new-data-for-melflufen-is-accepted-for-presentation-at-the-annual-american-society-of-hematology-meeting/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-hosts-a-virtual-capital-markets-day-on-november-30/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-anordnar-en-virtuell-kapitalmarknadsdag-den-30-november/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-har-ansokt-om-tillstand-att-starta-kliniska-studier-i-usa-med-den-andra-lakemedelskandidaten-fran-bolagets-pdc-plattform/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-has-submitted-an-investigational-new-drug-application-to-fda-for-the-second-drug-candidate-from-the-pdc-platform/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-nomination-committee-in-oncopeptides-established/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-valberedning-utsedd/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/extra-bolagsstamma-i-oncopeptides-ab-publ-2/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/press-releases/extraordinary-general-meeting-in-oncopeptides-ab-publ-2/ 2026-02-23T13:18:17+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-interim-report-q3-2020/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-delarsrapport-q3-2020/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-programmet-for-oncopeptides-virtuella-kapitalmarknadsdag-den-30-november-ar-publicerat/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-program-for-oncopeptides-virtual-capital-markets-day-on-november-30-is-published/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-7/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-7/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-extraordinary-general-meeting-in-oncopeptides-ab-publ/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-extra-bolagstamma-i-oncopeptides-ab-publ/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-new-data-from-phase-2-anchor-combination-study-in-multiple-myeloma-at-american-society-of-hematology-meeting-ash/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-nya-data-fran-fas-2-studien-anchor-i-multipelt-myelom-pa-den-amerikanska-hematologikongressen-ash/ 2026-02-23T13:18:16+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-full-data-set-of-oncopeptides-phase-2-horizon-study-in-multiple-myeloma-published-in-the-journal-of-clinical-oncology/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-fullstandiga-data-fran-oncopeptides-fas-2-studie-horizon-i-multipelt-myelom-publicerade-i-journal-of-clinical-oncology/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-forstarker-organisationen-genom-att-utse-linda-holmstrom-till-director-of-investor-relations/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-rekryterar-den-forsta-patienten-till-fas-3-studien-lighthouse-i-multipelt-myelom/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-year-end-report-2020/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-bokslutskommunike-2021/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-will-host-a-webcast-on-wednesday-december-9th-at-1400-cet-to-provide-an-update-regarding-data-presented-at-the-ash-annual-meeting/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-haller-en-webcast-onsdagen-den-9-december-klockan-1400-cet-avseende-data-som-presenteras-vid-ashs-arsmote/ 2026-02-23T13:18:15+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-that-the-first-patients-in-the-united-states-are-being-treated-with-pepaxto/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-meddelar-att-de-forsta-patienterna-i-usa-nu-behandlas-med-pepaxto/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-fda-approves-oncopeptides-pepaxto-melphalan-flufenamide-for-patients-with-relapsed-or-refractory-multiple-myeloma/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-far-fda-godkannande-for-pepaxto-for-patienter-med-relapserande-eller-refraktart-multipelt-myelom/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-starker-ledningen-i-europa-och-inleder-ett-early-access-program-i-multipelt-myelom/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-strengthens-leadership-in-europe-and-opens-an-early-access-program-in-multiple-myeloma/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-intends-to-carry-out-a-directed-share-issue/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-avser-att-genomfora-en-riktad-nyemission/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-has-completed-a-directed-share-issue-raising-approximately-sek-1106-million-usd-130-million/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-1-106-miljoner-kronor-130-miljoner-usd/ 2026-02-23T13:18:14+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-that-pepaxto-is-included-in-new-multiple-myeloma-guidelines-of-national-comprehensive-cancer-network/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-meddelar-att-pepaxto-ingar-i-nya-nationella-riktlinjer-i-usa-for-behandling-av-multipelt-myelom/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-6/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-6/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-submits-application-for-conditional-marketing-authorization-of-melflufen-in-the-eu/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-lamnar-in-ansokan-om-villkorat-marknadsgodkannande-for-melflufen-i-eu/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides-ab-publ-2/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides-ab-publ-2/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-the-2020-annual-report/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-arsredovisningen-for-2020/ 2026-02-23T13:18:13+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-nya-kliniska-och-prekliniska-data-for-melflufen-pa-european-hematology-associations-vetenskapliga-konferens/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-new-clinical-and-preclinical-melflufen-data-at-the-upcoming-european-hematology-association-meeting/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-clinical-abstracts-on-melflufen-at-the-2021-american-society-of-clinical-oncology/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-kliniska-data-for-melflufen-pa-vetenskapliga-konferensen-american-society-of-clinical-oncology/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-inbjudan-till-presentation-av-rapporten-for-det-forsta-kvartalet-2021/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-invitation-to-presentation-of-the-q1-2021-results/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-5/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-5/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-completes-patient-enrollment-in-phase-2-port-study/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-slutfor-patientrekryteringen-till-fas-2-studien-port/ 2026-02-23T13:18:12+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-phase-3-ocean-study-demonstrates-that-melflufen-is-at-least-as-efficacious-as-pomalidomide-the-most-used-medicine-in-relapsed-refractory-multiple-myeloma/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-fas-3-studien-ocean-visar-att-melflufen-ar-minst-lika-effektivt-som-pomalidomid-det-mest-anvanda-lakemedlet-i-relapserande-refraktart-multipelt-myelom/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-report-for-q1-2021-and-updated-dates-for-the-publication-of-the-reports-for-q2-and-q3-2021/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-rapporten-for-det-forsta-kvartalet-och-uppdaterade-datum-for-publiceringen-av-andra-och-tredje-kvartalet-2021/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ-2/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-arsstamma-i-oncopeptides-ab-publ-2/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-4/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-4/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-uppdaterade-resultat-fran-fas-3-studien-ocean-melflufen-nadde-primara-malet-superioritet-for-pfs-overlevnadsdata-leder-till-att-rekryteringen-av-patienter-i-kliniska-studier-pausas/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-updated-results-from-phase-3-ocean-study-shows-melflufen-met-primary-endpoint-of-superior-pfs-overall-survival-data-lead-to-partial-clinical-hold/ 2026-02-23T13:18:11+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-regulatorisk-uppdatering-fran-fda-2/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-regulatory-update-from-us-food-and-drug-administration-2/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-inbjudan-till-presentation-av-rapporten-for-det-andra-kvartalet-2021-2/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-invitation-to-presentation-of-the-q2-2021-results/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-rapporten-for-det-andra-kvartalet-2021/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-report-for-q2-2021/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-nya-data-fran-ocean-och-port-nu-tillgangliga-online/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-new-data-from-ocean-and-port-study-abstracts-online/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-regulatory-update-from-us-food-and-drug-administration/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-regulatorisk-uppdatering-fran-fda/ 2026-02-23T13:18:10+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-withdraws-pepaxto-in-us-scale-down-organization-and-focus-on-rd/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-drar-tillbaka-pepaxto-minskar-organisationen-och-fokuserar-pa-rd/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-utser-annika-muskantor-till-interim-cfo/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-appoints-annika-muskantor-as-interim-cfo/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-invitation-to-webcast-for-presentation-of-ocean-data-presented-at-imw/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-inbjudan-till-presentation-av-ocean-data-som-presenteras-pa-imw/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-phase-3-ocean-study-results-at-the-imw-meeting/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-nya-resultat-fran-fas-3-studien-ocean-pa-imw/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-cfo-anders-martin-lof-kommer-att-lamna-bolaget/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-cfo-anders-martin-lof-will-leave-the-company/ 2026-02-23T13:18:09+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-focuses-clinical-development-efforts-to-increase-cash-runway/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-fokuserar-det-kliniska-utvecklingsprogrammet-och-forstarker-kassan/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-has-announced-the-nomination-committee-2/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-har-utsett-valberedningen-2/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-jakob-lindberg-appointed-ceo-of-oncopeptides/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-jakob-lindberg-utnamnd-till-vd-for-oncopeptides/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-inbjudan-till-presentation-av-rapporten-for-det-andra-kvartalet-2021/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-invitation-to-presentation-of-the-q3-2021-results/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-q3-2021-report/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-rapporten-for-det-tredje-kvartalet-2021/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-nya-data-for-melflufen-pa-den-arliga-amerikanska-hematologikongressen-ash/ 2026-02-23T13:18:08+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-offentliggor-kassalikviditeten-per-den-31-december-2021/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-year-end-cash-2021/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-fas-3-studie-ocean-publicerad-i-the-lancet-haematology/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-phase-3-ocean-study-published-in-the-lancet-haematology/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-aterkallar-frivilliga-tillbakadragandet-av-pepaxto-i-usa-ingen-avsikt-att-marknadsfora-i-usa-i-nulaget/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-rescinds-voluntary-withdrawal-of-pepaxto-in-the-us-no-intent-to-market-in-the-us-at-this-time/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-inbjudan-till-presentation-av-bokslutskommuniken-for-2021/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-invitation-to-presentation-of-2021-year-end-results/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-new-melflufen-data-at-the-annual-american-society-of-hematology-meeting-ash/ 2026-02-23T13:18:07+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-rapporten-for-forsta-kvartalet-2022/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-q1-report-2022/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/press-releases/annual-general-meeting-in-oncopeptides-ab-publ/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-year-end-report-2021/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-bokslutskommuniken-for-2021/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-3/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-3/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-arsredovisningen-for-2021/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-the-2021-annual-report/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-inbjudan-till-presentation-av-q1-rapport/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-invitation-to-presentation-of-q1-report/ 2026-02-23T13:18:06+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/arsstamma-i-oncopeptides-ab-publ/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-chmp-issues-a-positive-opinion-recommending-full-approval-of-oncopeptides-pepaxti-in-eu-for-patients-with-triple-class-refractory-multiple-myeloma/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-chmp-rekommenderar-att-oncopeptides-pepaxti-far-ett-fullt-godkannande-i-eu-for-patienter-med-trippelklassrefraktart-multipelt-myelom/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-arsstamma-i-oncopeptides-ab-publ/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-the-annual-general-meeting-in-oncopeptides-ab-publ/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-has-carried-out-a-directed-share-issue-of-approximately-sek-435-6-million-approximately-usd-41-1-million/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-4356-msek-cirka-411-musd/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-fda-announces-an-oncologic-drugs-advisory-committee-meeting-to-discuss-benefit-risk-profile-of-oncopeptides-pepaxto/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-fda-anordnar-ett-mote-med-oncologic-drugs-advisory-committee-for-att-diskutera-nytta-riskprofilen-for-oncopeptides-pepaxto/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-2/ 2026-02-23T13:18:05+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-eu-kommissionen-godkanner-oncopeptides-pepaxti-for-behandling-av-patienter-med-trippelklassrefraktart-multipelt-myelom/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-european-commission-approves-oncopeptides-pepaxti-for-the-treatment-of-patients-with-relapsed-refractory-multiple-myeloma/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/extra-bolagsstamma-i-oncopeptides-ab-publ/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/press-releases/extraordinary-general-meeting-in-oncopeptides-ab-publ/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-beviljas-5-msek-i-anslag-for-nk-cellstimulering-i-multipelt-myelom/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-receives-5-msek-grant-for-nk-cell-engager-project-in-multiple-myeloma/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides-2/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-rapporten-for-andra-kvartalet-2022/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-q2-report-2022/ 2026-02-23T13:18:04+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-briefingbok-infor-odac-mote-om-nytta-riskprofilen-for-pepaxto-publicerad/ 2026-02-23T13:18:03+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-briefing-book-for-odac-meeting-on-benefit-risk-profile-of-pepaxto-now-published/ 2026-02-23T13:18:03+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-provides-an-update-from-the-meeting-with-fdas-advisory-committee-odac/ 2026-02-23T13:18:03+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-ger-en-uppdatering-fran-motet-med-fdas-radgivande-kommitte-odac/ 2026-02-23T13:18:03+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kommunike-fran-extra-bolagsstamma-i-oncopeptides-ab-pupl/ 2026-02-23T13:18:03+00:00 https://oncopeptides.com.haus.se/press-releases/bulletin-from-an-extra-ordinary-general-meeting-in-oncopeptides-ab-publ/ 2026-02-23T13:18:03+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-starts-commercialization-of-pepaxti-in-europe-germany-first-market/ 2026-02-23T13:18:03+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-inleder-kommersialiseringen-av-pepaxti-i-europa-tyskland-forsta-marknad/ 2026-02-23T13:18:02+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-emission-och-aterkop-av-c-aktier-for-aktieagarprogram-och-incitamentsprogram/ 2026-02-23T13:18:02+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-issue-and-re-purchase-of-class-c-shares-for-shareholder-program-and-incentive-program/ 2026-02-23T13:18:02+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-phase-3-lighthouse-study-further-confirms-clinical-benefit-of-melflufen/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-fas-3-studie-lighthouse-bekraftar-ytterligare-kliniska-nyttan-med-melflufen/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-antal-aktier-och-roster-i-oncopeptides/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-meddelar-marknadspotentialen-for-pepaxti-i-europa/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-announces-the-market-potential-for-pepaxti-in-europe/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-publicerar-rapporten-for-tredje-kvartalet-2022/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-publishes-q3-report-2022/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-pepaxti-har-fatt-marknadsgodkannande-i-storbritannien/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-pepaxti-has-been-granted-marketing-authorization-in-the-uk/ 2026-02-23T13:18:01+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-has-announced-the-nomination-committee/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-har-utsett-valberedningen/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-monica-shaw-appointed-ceo-of-oncopeptides-jakob-lindberg-assumes-position-as-chief-scientific-officer/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-monica-shaw-utsedd-till-vd-for-oncopeptides-jakob-lindberg-antar-rollen-som-chief-scientific-officer/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-enters-into-a-renewed-loan-facility-agreement-of-up-to-e30-million-with-the-european-investment-bank/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-ingar-ett-fornyat-laneavtal-med-europeiska-investeringsbanken-om-upp-till-30-miljoner-euro/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-provides-update-on-pepaxto-us-marketing-authorization/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-ger-uppdatering-om-marknadsforingstillstandet-for-pepaxto-i-usa/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-nya-vetenskapliga-data-pa-den-arliga-kongressen-for-american-society-of-hematology-ash/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-presents-new-scientific-data-at-the-annual-american-society-of-hematology-meeting-ash/ 2026-02-23T13:18:00+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-biostock-investor-pitch-oncopeptides/ 2026-02-23T13:17:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-presenterar-pa-biostock-life-science-summit-20-november/ 2026-02-23T13:17:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-utser-holger-lembrer-till-chief-financial-officer/ 2026-02-23T13:17:59+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-appoints-holger-lembrer-as-chief-financial-officer/ 2026-02-23T13:17:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/oncopeptides-ab-oncopeptides-chief-financial-officer-holger-lembrer-tilltrader-idag/ 2026-02-23T13:17:59+00:00 https://oncopeptides.com.haus.se/fi/press-releases/oncopeptides-omistusosuuden-paljastaminen/ 2026-02-23T13:17:59+00:00 https://oncopeptides.com.haus.se/sv/pressmeddelanden/kallelse-till-ordinarie-bolagsstamma/ 2026-02-23T13:17:58+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-will-present-at-the-biostock-life-science-summit-november-20/ 2026-02-23T08:36:22+00:00 https://oncopeptides.com.haus.se/press-releases/oncopeptides-ab-oncopeptides-chief-financial-officer-holger-lembrer-takes-office-today/ 2026-02-16T14:20:58+00:00